Correct. While ditching some other programmes that seemed less promising. It certainly seems like "direction".
Dear Winkleberry, what will it take to make you believe that someone/thing is very keen to have more of these? But they are patient and want to accumulate at the best price. Fear of failure gives them that opportunity.
Don't take it personally.
Https://www.theguardian.com/science/2024/jan/31/gene-therapy-hailed-as-medical-magic-wand-for-hereditary-swelling-disorder
Note that CRISPR needs a delivery system...
As usual, the buy/sell indicators with this one are IMO way off-beam. Not sure how they do it but I am sure the brokers do it. So I wouldn't be at all surprised to see an increase by end of day as I still feel someone/thing is accumulating here, with a lot of patience. On the other hand I wouldn't be surprised to see the price fall by the end of the day.... c'est la vie.
"... and not just chaff lifted from the web (not suggesting this is the latter)." Well, it wasn't. IMO it was a well-reasoned immunological and financial analysis, and almost certainly more neutral than you might get from almost any company or nominated broker which would, of course, be somewhat biased! Anyway let's leave it there - if folk want to read it they can.
"What is contained within the Interims in just a couple of weeks time, will overtake this ie. horses mouth." I suppose it's always true that the latest news surpasses everything else but, nevertheless, Sci102's report makes some interesting points -and far more insightful than 90% of the material on SCLP boards.
... of last week's frenzy? Someone much bigger wants this and it leaked. Everyone in on the leak rushed in to get their share until they were satisfied, knowing approximately what the outcome would be. No further insiders in the know so buying stopped and now they wait. I'm hoping not for long. Fanciful, yes, but we've seen everything over the last few years...
Picathartes .... never seen it, but I would love to!
RNS Number : 1234L
ReNeuron Group plc
04 September 2023
ReNeuron Group plc
("ReNeuron", the "Company" or the " Group")
R&D Update
Creating a valuable and differentiated Exosome Delivery Platform
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that it has successfully generated in vivo data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. The Company will now look to broaden its capabilities and focus on the functional delivery of specific payloads.
Randolph Corteling, Chief Scientific Officer, commented: "I am pleased to confirm that over the last six months we have generated comparative in vivo data demonstrating distinct organ and cellular targeting capabilities of our proprietary stem-cell derived exosomes, which differentiates our CustomEX(TM) platform from that of our competitors."
Iain Ross, Executive Chairman, said: "On the basis of this data the Company will now look to broaden its capabilities and, in liaison with partners and collaborators, focus on the functional delivery of specific payloads. We look forward to updating shareholders in due course."
Might be interesting?